Personalized cell therapy shows promise for tough cervical cancers

NCT ID NCT03108495

Terminated Disease control Sponsor: Iovance Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This phase 2 study tested a personalized treatment called LN-145 for women with recurrent or advanced cervical cancer. The therapy uses a patient's own tumor-fighting immune cells, grown in a lab and infused back. The trial aimed to see if it could shrink tumors, but it was terminated early, limiting the data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LN-145 (tumor infiltrating lymphocytes, a personalized cell therapy made from the patient's own immune cells)
What this could lead to: If successful, this could point toward a new treatment option for women with advanced cervical cancer that has not responded to standard therapies.
What could go wrong: The trial was terminated early, so results are limited. Cell therapies are complex, expensive, and may cause serious side effects like severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CARCINOMA

Contacts and locations

Locations

Academisch Medisch Centrum

Amsterdam, AZ, 1105, Netherlands
Allegheny Health

Pittsburgh, Pennsylvania, 15224, United States
Augusta University

Augusta, Georgia, 30912-0003, United States
Avera Medical Group Oncology

Sioux Falls, South Dakota, 57105, United States
Bristol Haematology and Oncology Centre

Bristol, England, BS2 8ED, United Kingdom
Centre Hospitalier Lyon Sud

Pierre-Bénite, Auvergne-Rhône-Alpes, 69495, France
Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie

Lausanne, Switzerland
Centre Léon Bérard

Lyon, 69008, France
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Clínica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Gustave Roussy Cancer Campus

Villejuif, 94805, France
Guy's & St.Thomas NHS Foundation Trust

London, SE1 9RT, United Kingdom
Hospital General Universitario Gregorio Marañon

Madrid, 28007, Spain
Hospital Universitari Vall d'Hebrón

Barcelona, 08035, Spain
Hospital Universitario Madrid Sanchinarro

Madrid, 28050, Spain
Inselspital

Bern, CH-3010, Switzerland
Institut Català d'Oncologia

Barcelona, 08908, Spain
Istituto Europeo di Oncologia

Miano, Milano, 20141, Italy
James Graham Brown Cancer Center

Louisville, Kentucky, 40202, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
LSU Health Sciences Center

New Orleans, Louisiana, 70112, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53225, United States
NHS Greater Glasgow and Clyde

Glasgow, Scotland, G12 0YN, United Kingdom
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rutgers University

Newark, New Jersey, 07103, United States
Sarah Cannon Research Institute London

London, England, W1G 6AD, United Kingdom
St. Joseph's Hospital and Medical Center Center For Women's Health

Phoenix, Arizona, 85013, United States
Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States
The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287-0013, United States
UPMC Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University College London Hospitals NHS Foundation Trust

London, England, W1G 6BW, United Kingdom
University of California San Diego

San Diego, California, 92093, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Florida Health Cancer Center

Orlando, Florida, 32806, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of South Florida H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
University of Southern California

Los Angeles, California, 90033, United States
University of Virginia

Charlottesville, Virginia, 22908, United States
Universitätsklinikum Carl Gustav Carus

Dresden, Saxony, 01307, Germany
Universitätsklinikum Erlangen

Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.